Pacira Q2 2026: Profit Swing, iovera Divestiture, and Payer Win Drive Thesis
PCRX sits 47% above its 52-week low of $18.8 on elevated volume (2.2× avg).
Summary
Pacira BioSciences reported a profitable Q2 2026, announced the completed divestiture of iovera for up to $140M, and secured a major payer win with UnitedHealthcare for EXPAREL, all while advancing its gene therapy pipeline.
Key Events · Earnings and Guidance · PCRX
-
Q2 Profit Swing
Net income of $4.7M versus a $4.8M loss in Q2 2025, on revenue of $192.4M (up 6% YoY). A $6.4M discrete tax benefit from a U.K. valuation allowance release boosted the bottom line.
-
iovera Divestiture Completed
Sold iovera cryoanalgesia business to Zimmer for up to $140M ($70M upfront, closed July 31). Sharpens focus on EXPAREL, ZILRETTA, and gene therapy pipeline.
-
Major Payer Win for EXPAREL
UnitedHealthcare now provides separate reimbursement for EXPAREL, expanding access to ~150M covered lives. Joins Aetna, Cigna, and others, removing a key financial barrier for patients.
-
Gene Therapy Milestone
PCRX-201 Phase 2 ASCEND trial Part A enrollment completed; topline 12-month data expected by end of 2026. Transitioned to a scalable commercial manufacturing process.
Analysis · PCRX · Life Sciences
A swing to a Q2 profit of $4.7M from a year-ago loss, fueled by 6% revenue growth and a $6.4M tax benefit, marks a pivotal quarter for Pacira. The completed divestiture of iovera to Zimmer for up to $140M ($70M upfront, closed July 31) sharpens the focus on core non-opioid pain therapies and the gene therapy pipeline. In a major commercial catalyst, UnitedHealthcare's decision to separately reimburse EXPAREL expands access to roughly 150 million covered lives. These results and strategic moves strengthen management's hand against the backdrop of an activist proxy battle. Meanwhile, the Phase 2 ASCEND trial for gene therapy PCRX-201 completed Part A enrollment, with topline data expected by year-end—a key value driver. A new headwind flagged for gross margins comes from tariffs on pharmaceutical imports.
At the time of this filing, PCRX was trading at $27.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $18.80 to $27.66. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.